Mercer Global Advisors Inc. ADV Has $202,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mercer Global Advisors Inc. ADV reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 50.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,641 shares of the specialty pharmaceutical company’s stock after selling 1,686 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Jazz Pharmaceuticals were worth $202,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of JAZZ. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $28,000. Allianz SE acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Jones Financial Companies Lllp lifted its stake in Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares in the company, valued at $1,189,587.54. The trade was a 36.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan acquired 100,000 shares of the stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the transaction, the director now owns 100,000 shares of the company’s stock, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 28,236 shares of company stock worth $3,956,190 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research reports. Barclays restated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. HC Wainwright raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Robert W. Baird cut their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $182.79.

Jazz Pharmaceuticals Stock Up 2.7%

NASDAQ JAZZ opened at $108.98 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a 50 day moving average of $115.73 and a 200-day moving average of $122.01. The company has a market cap of $6.72 billion, a price-to-earnings ratio of 15.35, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. During the same period last year, the business earned $2.68 earnings per share. The business’s revenue was down .5% compared to the same quarter last year. On average, equities research analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.